세계의 백신 보조제 시장 예측(-2029년) : 제품 유형별, ROA별, 질환 유형별, 백신별, 유형별

The global vaccine adjuvants market is projected to surpass USD 0.96 billion in 2029 from USD 0.70 billion in 2024, with a significant CAGR of 6.5%. Innovations in adjuvants, such as toll-like receptor agonists, emulsions, and saponin-based compounds, increased immunization programs in regions like Asia-Pacific, Latin America, and Africa, and rising demand for veterinary vaccines are some of the factors projecting growth of the vaccine adjuvants market.

"The emulsion-based adjuvants segment accounted for the highest share in 2023."

On the basis of product, the vaccine adjuvant market is segmented into emulsion-based adjuvants, pathogen components, saponin-based adjuvants, particulate-based adjuvants and other products. Emulsion-based adjuvants accounted for the dominant share due to their effectiveness in enhancing immune responses and diversified applications in various vaccine types such as infectious diseases, cancer, and others. The pathogen components segment is likely to grow at a significant CAGR owing to advancements in vaccine technology and increased demand for more targeted, effective vaccines.

" Organic adjuvant type dominated the market in 2023"

The adjuvant type segment is divided into organic and inorganic adjuvants. Organic adjuvants dominated the market in 2023. The factors attributable to their dominance are their versatility in various vaccine platforms (including mRNA and DNA vaccines) and their ability to enhance the immune response in both human and veterinary vaccines. Inorganic adjuvants are anticipated to grow at a significant CAGR owing to various factors such as safety profiles, efficacy, cost-effectiveness, and broad application across both human and veterinary vaccines.

" Infectious diseases segment held dominant share"

On the basis of disease type, the vaccine adjuvants market is segmented into infectious diseases, cancer, and other diseases. The infectious diseases segment dominated the market owing to the increasing prevalence of infectious diseases, the rise in immunization programs across the globe, and the rise in research & development funding. The cancer segment is likely to grow at a significant CAGR owing to the increased adoption of TLR agonists, oil-in-water emulsions, and cytokines in cancer vaccine development and the shift towards personalized vaccines.

"North America: the largest share of the vaccine adjuvants market"

The market is segmented by region into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America dominated the vaccine adjuvants market in 2023 and is estimated to continue dominance during the forecast period. The region's dominance is driven by advanced healthcare infrastructure, strong research and development activities, and the rising prevalence of infectious diseases and cancer. Furthermore, strong research & development for novel vaccine adjuvants and the presence of key market players in the region are some of the major factors projecting the growth of the market in the region.

In-depth interviews have been conducted with chief executive officers (CEOs), Directors, and other executives from various key organizations operating in the vaccine adjuvants market.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Tire 1 - 45%, Tire 2 - 35%, andTire 3 - 20%
• By Designation: Managers - 45%, CXO & Directors - 30%, and Executives - 25%
• By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5% and Middle East & Africa- 5%

GSK Plc (UK), Seppic (France), Croda International Plc (UK), SPI Pharma (UK), Phibro Animal Health Corporation (US), Agenus Inc. (US), Dynavax Technologies Corporation (US)are some of the major players operating in the vaccine adjuvants market.

Research Coverage:

This research report categorizes the vaccine adjuvants market product (driven by advanced healthcare infrastructure, strong research and development initiatives, and high cancer prevalence), adjuvant type (organic and inorganic), disease tye (infectious diseases, cancer, and others), application (commercial & research), vaccine type (human and veterinary), route of administration ( intramuscular, subcutaneous and other route of administration) nd region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the vaccine adjuvants market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, key strategies, collaborations, partnerships, and agreements. New launches, collaborations and acquisitions, and recent developments associated with the vaccine adjuvants market.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the vaccine adjuvants and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

• Analysis of key drivers (rising demand for vaccines and expanding government immunization programs, technological advancements & development of novel adjuvants, increasing livestock production and rising incidence of animal diseases, increased investment in research & development, and higher number of vaccines under pipeline), restraints (cost implications of vaccine adjuvant development and side effects and toxicity of adjuvants), opportunities (personalized and combination vaccines, increased investment in R&D plant-based vaccines and growth in companion animals market) and Challenges (concerns regarding animal-sourced vaccine adjuvants ) influencing the growth of the market.
• Product Development/Innovation: Detailed insights on upcoming technologies in vaccine adjuvants manufacturing, research and development activities, and new product launches in the vaccine adjuvants market.
• Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the vaccine adjuvants market
• Competitive Assessment: GSK Plc (UK), Sepppic (France), Croda International Plc (UK), SPI Pharma (UK) among others in the market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKETS COVERED & REGIONAL SCOPE
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
• 1.4 CURRENCY CONSIDERED
• 1.5 STAKEHOLDERS
• 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
  • 2.1.2 PRIMARY DATA
• 2.2 MARKET ESTIMATION METHODOLOGY
  • 2.2.1 MARKET ESTIMATION
  • 2.2.2 INSIGHTS FROM PRIMARY EXPERTS
  • 2.2.3 TOP-DOWN APPROACH
• 2.3 MARKET GROWTH RATE PROJECTIONS
• 2.4 DATA TRIANGULATION
• 2.5 RESEARCH ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
• 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 VACCINE ADJUVANTS MARKET OVERVIEW
• 4.2 NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY PRODUCT AND COUNTRY (2023)
• 4.3 VACCINE ADJUVANTS MARKET SHARE, BY VACCINE TYPE, 2024 VS. 2029
• 4.4 VACCINE ADJUVANTS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Rising demand for vaccines and expanding government immunization programs
    • 5.2.1.2 Technological advancements and development of novel adjuvants
    • 5.2.1.3 Increasing livestock production and rising incidence of animal diseases
    • 5.2.1.4 Increased investments in research & development and high number of vaccine adjuvants under pipeline
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Cost implications of vaccine adjuvant development
    • 5.2.2.2 Side effects and toxicity of adjuvants
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Personalized and combination vaccines
    • 5.2.3.2 Increased investments in R&D of plant-based vaccines
    • 5.2.3.3 Growth in companion animals market
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Concerns regarding animal-sourced vaccine adjuvants
• 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.4 PRICING ANALYSIS
  • 5.4.1 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER, 2022-2024
  • 5.4.2 AVERAGE SELLING PRICE OF PRODUCTS, BY REGION, 2024
• 5.5 SUPPLY CHAIN ANALYSIS
• 5.6 VALUE CHAIN ANALYSIS
• 5.7 ECOSYSTEM ANALYSIS
  • 5.7.1 VACCINE ADJUVANTS MARKET: RAW MATERIAL SUPPLIERS
  • 5.7.2 VACCINE ADJUVANTS MARKET: PRODUCT MANUFACTURERS
  • 5.7.3 VACCINE ADJUVANTS MARKET: END USERS
  • 5.7.4 VACCINE ADJUVANTS MARKET: REGULATORY BODIES
• 5.8 TECHNOLOGY ANALYSIS
  • 5.8.1 KEY TECHNOLOGIES
    • 5.8.1.1 Toll-like receptor (TLR) agonists
    • 5.8.1.2 Emulsion-based adjuvants
  • 5.8.2 COMPLEMENTARY TECHNOLOGIES
    • 5.8.2.1 Artificial intelligence (AI) and machine learning (ML)
  • 5.8.3 ADJACENT TECHNOLOGIES
    • 5.8.3.1 Nanotechnology in vaccine delivery
• 5.9 PATENT ANALYSIS
• 5.10 KEY CONFERENCES & EVENTS, 2024-2025
• 5.11 REGULATORY ANALYSIS
  • 5.11.1 REGULATORY LANDSCAPE
    • 5.11.1.1 North America
      • 5.11.1.1.1 US
      • 5.11.1.1.2 Canada
    • 5.11.1.2 Europe
    • 5.11.1.3 Asia Pacific
  • 5.11.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.12 INVESTMENT & FUNDING SCENARIO
• 5.13 PORTER'S FIVE FORCES ANALYSIS
  • 5.13.1 THREAT OF NEW ENTRANTS
  • 5.13.2 THREAT OF SUBSTITUTES
  • 5.13.3 BARGAINING POWER OF BUYERS
  • 5.13.4 BARGAINING POWER OF SUPPLIERS
  • 5.13.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.14 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.14.2 BUYING CRITERIA FOR END USERS
• 5.15 TRADE ANALYSIS
  • 5.15.1 IMPORT DATA
  • 5.15.2 EXPORT DATA
• 5.16 PIPELINE DATA FOR VACCINE ADJUVANTS
• 5.17 IMPACT OF AI/GENERATIVE AI ON VACCINE ADJUVANTS MARKET

6 VACCINE ADJUVANTS MARKET, BY PRODUCT

• 6.1 INTRODUCTION
• 6.2 EMULSION ADJUVANTS
  • 6.2.1 EXTENSIVE USE OF EMULSION ADJUVANTS IN HUMAN VACCINES TO DRIVE GROWTH
• 6.3 PATHOGEN COMPONENTS
  • 6.3.1 INCREASING NUMBER OF PROMINENT MARKET PLAYERS OFFERING BACTERIA-DERIVED ADJUVANTS TO DRIVE SEGMENTAL GROWTH
• 6.4 SAPONIN-BASED ADJUVANTS
  • 6.4.1 INCREASING USE AND GROWING DEMAND FOR SAPONIN-BASED ADJUVANTS TO DRIVE MARKET GROWTH
• 6.5 PARTICULATE-BASED ADJUVANTS
  • 6.5.1 GROWING POPULARITY OF MINERAL-BASED ADJUVANTS TO PROPEL MARKET
• 6.6 OTHER ADJUVANTS

7 VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE

• 7.1 INTRODUCTION
• 7.2 ORGANIC ADJUVANTS
  • 7.2.1 GROWING DEMAND FOR VACCINES WITH HIGH EFFICACY TO BOOST MARKET
• 7.3 INORGANIC ADJUVANTS
  • 7.3.1 INCREASING USE OF INORGANIC ADJUVANTS FOR VETERINARY VACCINE DEVELOPMENT TO SUPPORT MARKET GROWTH

8 VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION

• 8.1 INTRODUCTION
• 8.2 INTRAMUSCULAR
  • 8.2.1 INTRAMUSCULAR ROUTE TO BE LARGEST AND FASTEST-GROWING MARKET SEGMENT DURING FORECAST PERIOD
• 8.3 SUBCUTANEOUS
  • 8.3.1 WIDESPREAD USE OF SUBCUTANEOUS ROUTE OF ADMINISTRATION TO BOOST MARKET
• 8.4 OTHER ROUTES OF ADMINISTRATION

9 VACCINE ADJUVANTS MARKET, BY DISEASE TYPE

• 9.1 INTRODUCTION
• 9.2 INFECTIOUS DISEASES
  • 9.2.1 INCREASED PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET
• 9.3 CANCER
  • 9.3.1 INCREASING DEMAND FOR NOVEL CANCER VACCINES TO SUPPORT MARKET GROWTH
• 9.4 OTHER DISEASES

10 VACCINE ADJUVANTS MARKET, BY APPLICATION

• 10.1 INTRODUCTION
• 10.2 RESEARCH APPLICATIONS
  • 10.2.1 EXTENSIVE R&D FOR DEVELOPMENT OF VACCINE ADJUVANTS TO DRIVE MARKET
• 10.3 COMMERCIAL APPLICATIONS
  • 10.3.1 GROWING USE OF VACCINE ADJUVANTS FOR COMMERCIAL APPLICATIONS TO SUPPORT MARKET GROWTH

11 VACCINE ADJUVANTS MARKET, BY VACCINE TYPE

• 11.1 INTRODUCTION
• 11.2 HUMAN VACCINES
  • 11.2.1 INFECTIOUS DISEASES
    • 11.2.1.1 Rising prevalence of infectious diseases to drive market growth
  • 11.2.2 THERAPEUTIC
    • 11.2.2.1 Rising investments in development of therapeutic vaccines to boost market
• 11.3 VETERINARY VACCINES
  • 11.3.1 COMPANION ANIMALS
    • 11.3.1.1 Increasing pet ownership and rising focus on pet health and wellness to play key role in driving market growth
  • 11.3.2 LIVESTOCK ANIMALS
    • 11.3.2.1 Increasing demand for high-quality meat, dairy, and other animal products to aid growth
  • 11.3.3 OTHER ANIMALS

12 VACCINE ADJUVANTS MARKET, BY REGION

• 12.1 INTRODUCTION
• 12.2 NORTH AMERICA
  • 12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 12.2.2 US
    • 12.2.2.1 US to dominate North American market during forecast period
  • 12.2.3 CANADA
    • 12.2.3.1 Increasing government funding for vaccine research to drive market growth in Canada
• 12.3 EUROPE
  • 12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 12.3.2 GERMANY
    • 12.3.2.1 Increasing investments by various key players and growing funding from government organizations to drive market
  • 12.3.3 UK
    • 12.3.3.1 Rising investments in vaccine development to boost market growth
  • 12.3.4 FRANCE
    • 12.3.4.1 Focus on new vaccine development to drive market growth
  • 12.3.5 ITALY
    • 12.3.5.1 Government initiatives for vaccine development to boost market growth
  • 12.3.6 SPAIN
    • 12.3.6.1 Increasing investments in vaccine development by government and private organizations to support market growth in Spain
  • 12.3.7 REST OF EUROPE
• 12.4 ASIA PACIFIC
  • 12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 12.4.2 CHINA
    • 12.4.2.1 Government support & strategic initiatives by key players to strengthen biotechnology sector in China
  • 12.4.3 JAPAN
    • 12.4.3.1 Government initiatives for vaccines to boost market
  • 12.4.4 INDIA
    • 12.4.4.1 Growth of biotechnology sector and development of new vaccines to support market growth in India
  • 12.4.5 SOUTH KOREA
    • 12.4.5.1 Strategic collaborations to expand both human and veterinary vaccine sectors in South Korea
  • 12.4.6 AUSTRALIA
    • 12.4.6.1 Government support and strategic alliances to drive market
  • 12.4.7 REST OF ASIA PACIFIC
• 12.5 LATIN AMERICA
  • 12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 12.5.2 BRAZIL
    • 12.5.2.1 Robust healthcare infrastructure and thriving livestock industry to support market growth
  • 12.5.3 MEXICO
    • 12.5.3.1 Government commitment to immunization programs to fuel growth
  • 12.5.4 ARGENTINA
    • 12.5.4.1 Growing pharmaceutical sector to drive growth in Argentina
  • 12.5.5 REST OF LATIN AMERICA
• 12.6 MIDDLE EAST
  • 12.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
  • 12.6.2 GCC COUNTRIES
    • 12.6.2.1 Saudi Arabia
      • 12.6.2.1.1 Strategic emphasis on advancing vaccine development for both human and veterinary applications to fuel growth
    • 12.6.2.2 United Arab Emirates (UAE)
      • 12.6.2.2.1 Increasing focus on developing cutting-edge vaccine technologies to contribute to market growth
    • 12.6.2.3 Rest of GCC countries
  • 12.6.3 REST OF MIDDLE EAST
• 12.7 AFRICA
  • 12.7.1 INCREASING INVESTMENTS IN VACCINE PRODUCTION FACILITIES TO SUPPORT MARKET GROWTH
  • 12.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

13 COMPETITIVE LANDSCAPE

• 13.1 OVERVIEW
• 13.2 KEY PLAYER STRATEGY/RIGHT TO WIN, 2023
  • 13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN VACCINE ADJUVANTS MARKET
• 13.3 REVENUE ANALYSIS, 2019-2023
• 13.4 MARKET SHARE ANALYSIS, 2023
• 13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 13.5.1 STARS
  • 13.5.2 EMERGING LEADERS
  • 13.5.3 PERVASIVE PLAYERS
  • 13.5.4 PARTICIPANTS
  • 13.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 13.5.5.1 Company footprint
    • 13.5.5.2 Product footprint
    • 13.5.5.3 Application footprint
    • 13.5.5.4 Region footprint
• 13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 13.6.1 PROGRESSIVE COMPANIES
  • 13.6.2 RESPONSIVE COMPANIES
  • 13.6.3 DYNAMIC COMPANIES
  • 13.6.4 STARTING BLOCKS
  • 13.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
• 13.7 COMPANY VALUATION & FINANCIAL METRICS
  • 13.7.1 FINANCIAL METRICS
  • 13.7.2 COMPANY VALUATION
• 13.8 BRAND/PRODUCT COMPARISON
• 13.9 COMPETITIVE SCENARIO
  • 13.9.1 PRODUCT LAUNCHES & APPROVALS
  • 13.9.2 DEALS
  • 13.9.3 EXPANSIONS

14 COMPANY PROFILES

• 14.1 KEY PLAYERS
  • 14.1.1 GSK PLC
    • 14.1.1.1 Business overview
    • 14.1.1.2 Products offered
    • 14.1.1.3 Recent developments
      • 14.1.1.3.1 Deals
    • 14.1.1.4 MnM view
      • 14.1.1.4.1 Key strengths
      • 14.1.1.4.2 Strategic choices
      • 14.1.1.4.3 Weaknesses & competitive threats
  • 14.1.2 SEPPIC (A SUBSIDIARY OF AIR LIQUIDE GROUP)
    • 14.1.2.1 Business overview
    • 14.1.2.2 Products offered
    • 14.1.2.3 Recent developments
      • 14.1.2.3.1 Product launches
    • 14.1.2.4 MnM view
      • 14.1.2.4.1 Key strengths
      • 14.1.2.4.2 Strategic choices
      • 14.1.2.4.3 Weaknesses & competitive threats
  • 14.1.3 CRODA INTERNATIONAL PLC
    • 14.1.3.1 Business overview
    • 14.1.3.2 Products offered
    • 14.1.3.3 Recent developments
      • 14.1.3.3.1 Deals
      • 14.1.3.3.2 Expansions
    • 14.1.3.4 MnM view
      • 14.1.3.4.1 Key strengths
      • 14.1.3.4.2 Strategic choices
      • 14.1.3.4.3 Weaknesses & competitive threats
  • 14.1.4 PHIBRO ANIMAL HEALTH CORPORATION
    • 14.1.4.1 Business overview
    • 14.1.4.2 Products offered
    • 14.1.4.3 MnM view
      • 14.1.4.3.1 Key strengths
      • 14.1.4.3.2 Strategic choices
      • 14.1.4.3.3 Weaknesses & competitive threats
  • 14.1.5 SPI PHARMA (A SUBSIDIARY OF ASSOCIATED BRITISH FOODS PLC)
    • 14.1.5.1 Business overview
    • 14.1.5.2 Products offered
    • 14.1.5.3 MnM view
      • 14.1.5.3.1 Key strengths
      • 14.1.5.3.2 Strategic choices
      • 14.1.5.3.3 Weaknesses & competitive threats
  • 14.1.6 AGENUS INC.
    • 14.1.6.1 Business overview
    • 14.1.6.2 Products offered
    • 14.1.6.3 Recent developments
      • 14.1.6.3.1 Deals
  • 14.1.7 NOVAVAX
    • 14.1.7.1 Business overview
    • 14.1.7.2 Products offered
  • 14.1.8 AURORIUM (FORMERLY VERTELLUS)
    • 14.1.8.1 Business overview
    • 14.1.8.2 Products offered
    • 14.1.8.3 Recent developments
      • 14.1.8.3.1 Deals
  • 14.1.9 DYNAVAX TECHNOLOGIES CORPORATION
    • 14.1.9.1 Business overview
    • 14.1.9.2 Products offered
    • 14.1.9.3 Recent developments
      • 14.1.9.3.1 Deals
  • 14.1.10 MERCK KGAA
    • 14.1.10.1 Business overview
    • 14.1.10.2 Products offered
  • 14.1.11 VAXINE PTY LTD.
    • 14.1.11.1 Business overview
    • 14.1.11.2 Products offered
  • 14.1.12 HAWAII BIOTECH INC.
    • 14.1.12.1 Business overview
    • 14.1.12.2 Products offered
  • 14.1.13 CSL LIMITED
    • 14.1.13.1 Business overview
    • 14.1.13.2 Products offered
  • 14.1.14 OZ BIOSCIENCES
    • 14.1.14.1 Business overview
    • 14.1.14.2 Products offered
  • 14.1.15 INVIVOGEN
    • 14.1.15.1 Business overview
    • 14.1.15.2 Products offered
• 14.2 OTHER PLAYERS
  • 14.2.1 ALLERGY THERAPEUTICS
  • 14.2.2 EUBIOLOGICS CO., LTD.
  • 14.2.3 PACIFIC GENETECH LIMITED
  • 14.2.4 RIBOXX GMBH
  • 14.2.5 CAPTIVATE PHARMACEUTICALS LLC
  • 14.2.6 CREATIVE DIAGNOSTICS
  • 14.2.7 LITEVAX B.V.
  • 14.2.8 MUKTA INDUSTRIES
  • 14.2.9 ONCOVIR, INC.
  • 14.2.10 TITERMAX USA, INC.

15 APPENDIX

• 15.1 DISCUSSION GUIDE
• 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 15.3 CUSTOMIZATION OPTIONS
• 15.4 RELATED REPORTS
• 15.5 AUTHOR DETAILS